ea0029p1652 | Thyroid (non-cancer) | ICEECE2012
Vannucchi G.
, Campi I.
, Covelli D.
, Curro N.
, Cirello V.
, Dazzi D.
, Beck-Peccoz P.
, Salvi M.
We have retrospectively studied the clinical outcome of 58 patients (14 men and 44 women) with autoimmune thyroid disease and active GO, treated with high dose intravenous methylprednisolone (MP; cumulative dose 7.5 g). Ophthalmological assessment was performed at baseline and at 6, 12 and 2430 weeks after the first MP infusion. In 43/58 patients we have also studied NR3C1gene polymorphism, which has been associated to different sensitivity to steroids. The therapeutic o...